business / news / / CNBC
Eli Lilly's Indian market share fell to 56% in March from 61% a month earlier.
Eli Lilly's GLP-1 market share in India fell from 61% to 56% in March 2024.
KEY POINTS
- Thirteen Indian generic companies launched 26 semaglutide brands within weeks of patent expiry.
- Novo Nordisk cut Ozempic and Wegovy prices by 38% and 48% respectively in India.
- Some Indian generic semaglutide versions are priced as low as 1,290 rupees per month.
- India's GLP-1 market is projected to grow nearly five-fold to 50 billion rupees by 2030.
COMPANIES
Summarized by Newsio from CNBC. How we summarize →